Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral mRNA RSV Vaccine
- Development stage
- Preclinical
- Lead developer
- Esperovax
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The Oral mRNA RSV Vaccine is an investigational mRNA-based oral vaccine being developed by Esperovax for the prevention of Respiratory Syncytial Virus (RSV) infection. Utilizing the proprietary Egress platform, the vaccine employs modified yeast cells encapsulated in an oral delivery format, such as a capsule or tablet. Upon ingestion, the yeast cells are engineered to synthesize mRNA just before reaching the small intestine, where the mRNA is delivered to immune cells in the gastrointestinal tract. These cells then translate the mRNA into viral antigens, triggering both mucosal and systemic immune responses. This approach aims to provide a thermostable and non-invasive alternative to traditional injectable vaccines, leveraging the high concentration of immune cells in the gut to stimulate protective immunity.
- Other names
- Esperovax RSV vaccineOral RSV mRNA vaccine
Beyond the preview
Go deeper on Oral mRNA RSV Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oral mRNA RSV Vaccine.